SCHEMBL5083434

SCHEMBL5083434

CS(=O)(=O)c1ccc(-c2ccc(NCC3CCN(C(=O)CC4CCCCC4)CC3)nc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.52
HSD17B10 Q99714 2/20 0.52
TSHR P16473 1/20 0.52
PTGS2 P35354 2/20 0.48
ALDH1A1 P00352 4/20 0.45
POLB P06746 2/20 0.45
HTT P42858 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
LMNA P02545 1/20 0.45
CYP3A4 P08684 1/20 0.45
MAPT P10636 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
USP30 Q70CQ3 1/20 0.41
GPR119 Q8TDV5 1/20 0.40
CKS1B P61024 1/20 0.40
SKP1 P63208 1/20 0.40
SKP2 Q13309 1/20 0.40
JAK2 O60674 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3982989 0.90 KDM4E (0.48) KDM4EHSD17B10TSHRPTGS2ALDH1A1
SCHEMBL3979867 0.89 KDM4E (0.51) KDM4EHSD17B10TSHRPTGS2ALDH1A1
SCHEMBL3978507 0.86 USP30 (0.47) KDM4EHSD17B10TSHRPTGS2CYP3A4
SCHEMBL3983755 0.85 KDM4E (0.43) KDM4EHSD17B10TSHRPTGS2USP30
SCHEMBL3986036 0.83 GRIN2B (0.48) KDM4EHSD17B10TSHRALDH1A1SMN1; SMN2
SCHEMBL3983168 0.82 ALDH1A1 (0.45) KDM4EHSD17B10PTGS2ALDH1A1POLB
SCHEMBL3982528 0.81 KDM4E (0.40) KDM4EHSD17B10TSHRPTGS2USP30
SCHEMBL5083458 0.81 GPR119 (0.60) GPR119
SCHEMBL3983646 0.80 KDM4E (0.48) KDM4EHSD17B10TSHRPTGS2USP30
SCHEMBL3983386 0.80 GPR119 (0.56) KDM4EHSD17B10TSHRCYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080103123-A1 New compounds BIOVITRUM (SE) 2008-05-01 US claimed
US-20080103123-A1 New compounds BIOVITRUM (SE) 2008-05-01 US disclosed
US-20080103123-A1 New compounds BIOVITRUM (SE) 2008-05-01 US disclosed
US-20080103123-A1 New compounds BIOVITRUM (SE) 2008-05-01 US disclosed
WO-2008025798-A1 PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS BIOVITRUM AB (PUBL) (SE) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103123-A1 New compounds GPR119, GPR139, GPR180 KDM4E 4829/4885HSD17B10 658/4885TSHR 488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.